Lenvatinib (Lenv) plus tislelizumab (Tis) combined with or without transarterial chemoembolization (TACE) in first-line treatment of unresectable hepatocellular carcinoma (uHCC): A prospective, non-randomized, open-label, phase II cohort study.

被引：0
|
作者：
Zhang, Nan
Li, Jiongyuan
Piao, Mingjian
Li, Chengjie
Xun, Ziyu
Zhang, Longhao
Wang, Yanyu
Liu, Kai
Wang, Shanshan
Wang, Hanping
Zhao, Hai-Tao
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Liver Surg, State Key Lab Complex Severe & Rare Dis, Beijing, Peoples R China
[2] Peking Union Med Coll & Chinese Acad Med Sci, Div Pulm & Crit Care Med, State Key Lab Severe & Rare Dis, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16169
引用
收藏
页数：1
相关论文
共 50 条
  • [21] TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization combined with atezolizumab plus bevacizumab or on-demand transarterial chemoembolization alone in patients with untreated hepatocellular carcinoma
    Kudo, Masatoshi
    Guo, Yabing
    Hua, Yongqiang
    Zhao, Ming
    Xing, Wenge
    Zhang, Yonghong
    Liu, Ruibao
    Ren, Zhenggang
    Gu, Shanzhi
    Lin, Zhengyu
    Lv, Weifu
    Wang, Yumeng
    Dong, Jiahong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [22] The efficacy and safety of toripalimab combined with sorafenib for unresectable hepatocellular carcinoma: An open-label, prospective, single-arm phase II study.
    Yang, Xin-Rong
    Cheng, Jian-Wen
    Wu, Suiyi
    Hu, Bo
    Qiu, Shuang-Jian
    Sun, Hui-Chuan
    Fan, Jia
    Zhou, Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial
    Xu, Ling-Xiao
    Yuan, Jia-Jia
    Xue, Ran
    Zhou, Jun
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (30)
  • [24] LEAP-014: An open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma
    Sun, Jong-Mu
    Enzinger, Peter C.
    Adenis, Antoine
    Shah, Manish A.
    Kato, Ken
    Bennouna, Jaafar
    Doi, Toshihiko
    Hawk, Natalyn Nicole
    Yu, Li
    Shah, Sukrut
    Bhagia, Pooja
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [25] Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study
    Zhang, Qiyi
    Liu, Xingyu
    Wei, Shumei
    Zhang, Lufei
    Tian, Yang
    Gao, Zhenzhen
    Jin, Ming
    Yan, Sheng
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [26] Tislelizumab plus anlotinib with or without radiotherapy as first-line therapy in advanced hepatocellular carcinoma: a single center, non-randomized retrospective case-control study
    Wu, Guishu
    Liu, Yuhong
    Fan, Huaxi
    Rao, Mingyue
    Zhang, Jing
    Zhang, Jianwen
    DISCOVER ONCOLOGY, 2025, 16 (01)
  • [27] Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
    Qin, Shukui
    Bi, Feng
    Gu, Shanzhi
    Bai, Yuxian
    Chen, Zhendong
    Wang, Zishu
    Ying, Jieer
    Lu, Yinying
    Meng, Zhiqiang
    Pan, Hongming
    Yang, Ping
    Zhang, Helong
    Chen, Xi
    Xu, Aibing
    Cui, Chengxu
    Zhu, Bo
    Wu, Jian
    Xin, Xiaoli
    Wang, Jufeng
    Shan, Jinlu
    Chen, Junhui
    Zheng, Zhendong
    Xu, Li
    Wen, Xiaoyu
    You, Zhenyu
    Ren, Zhenggang
    Liu, Xiufeng
    Qiu, Meng
    Wu, Liqing
    Chen, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (27) : 3002 - +
  • [28] Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial
    Vogel, Arndt
    Qin, Shukui
    Kudo, Masatoshi
    Su, Yun
    Hudgens, Stacie
    Yamashita, Tatsuya
    Yoon, Jung-Hwan
    Fartoux, Laetitia
    Simon, Krzysztof
    Lopez, Carlos
    Sung, Max
    Mody, Kalgi
    Ohtsuka, Tatsuroh
    Tamai, Toshiyuki
    Bennett, Lee
    Meier, Genevieve
    Breder, Valery
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (08): : 649 - 658
  • [29] Penpulimab (Anti-PD-1) combined with anlotinib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Updated results from a phase Ib/II study.
    Jiao Shun Chang
    Bai Li
    Dong Jiahong
    Bai Chunmei
    Hu Chunhong
    Shen Liangfang
    Qin Qun
    Bai Yuxian
    Fan Jia
    Zang Aimin
    Zhu Yanyun
    Han Chun
    Li Juan
    Zhang Pengfei
    Ye Sisi
    Kang Xindan
    Qiao Qian
    Wang, Zhongmin Maxwell
    Li Baiyong
    Xia Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [30] Camrelizumab in combination with fluorouracil or taxol plus platinum chemotherapy as first-line treatment of esophageal squamous cell carcinoma: A multicenter, open-label, prospective cohort study.
    Zhao, Jun
    Hu, Wenqing
    Zhang, Xiaoling
    Du, Yunyi
    Yao, Chunmei
    Ma, Ning
    Yang, Wei
    Yang, Bo
    Xue, Yudong
    Gao, Yangjun
    Wang, Yu
    Liu, Min
    Wang, Mei
    Wang, Hui
    Feng, Tingting
    Cai, Linlin
    Zhang, Cuihua
    Ma, Kai
    Xu, Ning
    Lu, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16084 - E16084
12345